The novel EZH2 inhibitor tazemetostat has shown clinically meaningful benefit in patients with relapsing or refractory follicular lymphoma regardless of EZH2 mutation status. The phase 2 study, involving 99 patients from nine countries including Australia, tested 800mg tazemetostat orally twice daily in consecutive 28-day cycles. It found an overall response of 69% in patients with ...
Tazemetostat promising in RR follicular lymphoma
By Mardi Chapman
14 Oct 2020